127 results
Page 4 of 7
8-K
EX-99.1
iz6cu01zmbx46l
13 May 21
Equillium Reports First Quarter 2021 Financial Results and Provides Clinical Development Update
4:13pm
8-K
EX-99.1
tl864g85p 2ok
30 Mar 21
Equillium Announces Favorable Data From Phase 1b EQUALISE Study in Systemic Lupus Erythematosus Patients
4:52pm
8-K
EX-99.1
74soa4k
24 Mar 21
Equillium Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Clinical Development Update
4:10pm
8-K
EX-99.1
9i3qhiry vc68u
15 Mar 21
Regulation FD Disclosure
8:02am
8-K
EX-99.1
ozdg5nw9
9 Mar 21
Regulation FD Disclosure
7:00am
8-K
EX-99.2
51fnnz4 9u14d1x
12 Feb 21
Regulation FD Disclosure
3:05pm
8-K
EX-99.1
u7eyoogiexod3w
12 Feb 21
Regulation FD Disclosure
3:05pm
8-K
EX-99.1
jj3005wo1nz56
4 Feb 21
Equillium Announces Pricing of $30 Million Registered Direct Offering
8:10am
424B5
k86zbf4 dkfq
4 Feb 21
Prospectus supplement for primary offering
8:07am
8-K
EX-99.1
9qb9 ghshzh
21 Dec 20
Equillium Appoints Industry Veteran, Dolca Thomas, M.D. as Executive Vice President of
8:06am
8-K
EX-10.1
yy28y29bb3y7
21 Dec 20
Equillium Appoints Industry Veteran, Dolca Thomas, M.D. as Executive Vice President of
8:06am
8-K
EX-99.1
qzkjllyc1t4m16
7 Dec 20
Equillium Presents Translational Data Demonstrating Impact of Itolizumab on Effector T Cell
9:24am
8-K
EX-99.1
c7qzchoxdko7d
4 Dec 20
Regulation FD Disclosure
9:07am
8-K
EX-99.1
e9j5 wfod7i67o
30 Nov 20
Regulation FD Disclosure
8:01am
8-K
EX-99.1
a7k0qtucim
25 Nov 20
Equillium Provides Itolizumab COVID-19 Program Update
8:01am
8-K
EX-99.1
0l7yqnn 1bv7d
10 Nov 20
Equillium Reports Third Quarter 2020 Financial Results and Business Highlights
4:11pm
8-K
EX-99.1
bat9eo fe8dpwth7w
29 Oct 20
Equillium Receives FDA Clearance of COVID-19 IND for Phase 3 Trial
5:12pm